Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021
Cited by 387 works. doi:10.1016/s1470-2045(21)00065-6
Authors
- Alexander M.M. Eggermont
- Christian U. Blank
- Mario Mandalà
- Georgina Venetia Long
- Victoria G. Atkinson
- Stéphane Dalle
- Andrew Mark Haydon
- Andrey Meshcheryakov
- Adnan Khattak
- Matteo Salvatore Carlino
- Shahneen Kaur Sandhu
- James Larkin
- Susana Puig
- Paolo A. Ascierto
- Piotr Lukasz Rutkowski
- Dirk Schadendorf
- Rutger H.T. Koornstra
- Leonel Fernando Hernandez-Aya
- Anna Maria Di Giacomo
- Alfons J.M. van den Eertwegh
References
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- Cutaneous melanoma